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Abstract
Background: Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass
and bone strength. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to progressive
muscle degeneration and also high incidence of fractures. The aim of our study was to test whether inhibition of
activin receptor IIB ligands with or without exercise could improve bone strength in the mdx mouse model for DMD.
Methods: Thirty-two mdx mice were divided to running and non-running groups and to receive either PBS control or
soluble activin type IIB-receptor (ActRIIB-Fc) once weekly for 7 weeks.
Results: Treatment of mdx mice with ActRIIB-Fc resulted in significantly increased body and muscle weights in
both sedentary and exercising mice. Femoral μCT analysis showed increased bone volume and trabecular number
(BV/TV +80%, Tb.N +70%, P < 0.05) in both ActRIIB-Fc treated groups. Running also resulted in increased bone volume
and trabecular number in PBS-treated mice. However, there was no significant difference in trabecular bone structure
or volumetric bone mineral density between the ActRIIB-Fc and ActRIIB-Fc-R indicating that running did not further
improve bone structure in ActRIIB-Fc-treated mice. ActRIIB-Fc increased bone mass also in vertebrae (BV/TV +20%,
Tb.N +30%, P < 0.05) but the effects were more modest. The number of osteoclasts was decreased in histological
analysis and the expression of several osteoblast marker genes was increased in ActRIIB-Fc treated mice suggesting
decreased bone resorption and increased bone formation in these mice. Increased bone mass in femurs translated into
enhanced bone strength in biomechanical testing as the maximum force and stiffness were significantly elevated in
ActRIIB-Fc-treated mice.
Conclusions: Our results indicate that treatment of mdx mice with the soluble ActRIIB-Fc results in a robust increase in
bone mass, without any additive effect by voluntary running. Thus ActRIIB-Fc could be an attractive option in the
treatment of musculoskeletal disorders.
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Background
Inhibition of the activin/myostatin pathway has recently
emerged as a potential therapeutic approach for the
treatment of osteoporosis. Activins are a group of multi-
functional growth factors belonging to the TGF-β super-
family that play multiple roles in many physiological and
systemic processes such as secretion of follistatin-
stimulating hormone, wound healing, morphogenesis,
and tooth formation [1–3]. Myostatin in turn inhibits
muscle development and its inhibition leads to increased
muscle mass [2, 3]. Activins and myostatin signal via
activin type IIA or type IIB receptors [4]. The role of
activins in bone physiology remained unclear until re-
cent studies indicated that inhibition of activin receptor
ligands leads to increased bone mass [5, 6]. In these ex-
periments, soluble activin receptor-Fc fusion proteins
were used as decoy receptors harvesting and thus inhi-
biting their ligands including activin A and myostatin.
These studies suggested that inhibition of activin path-
way could be a promising therapeutic target for meta-
bolic bone diseases [7]. The use of a soluble activin type
IIA-receptor has been shown to increase bone mass in
several in vivo [5, 6, 8] models. The effects of soluble
activin type IIB-receptor (ActRIIB-Fc) on bone metabol-
ism have also been studied recently [9–12]. Furthermore,
exercise, in addition to its various other health benefits,
may have positive effects on bones of young individuals
[13, 14]. Previously, the effects of exercise have also been
investigated in a model of increased body mass through
increased fat, not muscle mass [15]. In that model aer-
obic exercise does not further increase bone strength
when compared to increased body mass alone suggesting
interaction between physical activity and increased body
mass. However, increasing body weight through muscle
mass in combination with exercise has not been investi-
gated before.
Duchenne muscular dystrophy (DMD) is a neuromus-
cular disease that is caused by a single mutation in the
dystrophin gene. Patients suffering from this disorder
are left immobilized and eventually are often deceased
around the age of 20 [16]. Duchenne muscular dys-
trophy is also known to lead to secondary osteoporosis
and increased fracture risk, at least in part due to the re-
duced mobility of DMD patients [16, 17]. By improving
both muscle and bone function and strength, patient
mobility could be prolonged and quality of life increased.
The effects of exercise on bones in DMD as well as the
interaction of the physical activity with ActRIIB-Fc lig-
and blocking are not known.
Muscle and bone tissues interact in multiple ways and
muscle tissue can directly induce bone formation locally
via several different molecular pathways [18, 19]. Fur-
ther, muscle and body masses per se can also indirectly
effect bone [20]. There is also reciprocal signaling from
bone to muscle [21]. Myostatin and activins are inhibi-
tors of muscle growth and their inhibition could have
therapeutic implications in frailty and other diseases
with muscle wasting [4, 22]. Intriguingly, ActRIIB-Fc can
block both activin A as well as myostatin [23], that could
potentially be very beneficial in conditions, such as frailty
and DMD, which involve both muscle and bone [9].
Based on the previous data, we hypothesized that in-
hibition of the activin/myostatin pathway could provide
a novel dual-effect treatment approach for musculoskel-
etal conditions improving both the muscle and bone
properties. We aimed to answer the following questions:
1) does inhibition of activin receptor ligands with the
use of a soluble activin type IIB-receptor (ActRIIB-Fc)
affect bone volume and quality in a muscle dystrophy
(mdx) mouse model [24] parallel to changes in muscle
mass and 2) is there an interaction between ActRIIB-Fc
treatment and low-intensity aerobic exercise.
Methods
Animals
In this experiment 6- to 7 week-old muscle dystrophy
(mdx) male mice from a C57Bl/10ScSnJ background were
used (Jackson Laboratory, Bar Harbor, Maine, USA). The
mice were housed in standard laboratory conditions
(temperature 22°C, light from 8:00 AM to 8:00 PM) and
had free access to tap water and food pellets (R36, 4% fat,
55.7% carbohydrate, 18.5% protein, 3 kcal/g, Labfor,
Stockholm Sweden).
Experimental design
Thirty-two male mice were evenly divided into four
groups: 1) PBS control group, 2) ActRIIB-Fc group, 3)
PBS running group (PBS-R) and 4) ActRIIB-Fc running
group (ActRIIB-Fc-R). PBS or ActRIIB-Fc was injected
intraperitoneally once a week with a 5mg/kg dose. The
chosen exercise modality was voluntary wheel running.
To allow the treatment to take effect, the running
wheels were locked during the first injection day and the
following day preventing mice from exercising. On the
last two days, the mice did not have access to running
wheels so that the possible acute exercise effects would
not affect the outcome. During the experiments all con-
ditions were standardized. Mice were euthanized by cer-
vical dislocation at the end of the experiment, after
which tissue samples were harvested. One specimen
from the ActRIIB-Fc-R group was moved to the
ActRIIB-Fc group due to no voluntary running activity.
Production of soluble ActRIIB-Fc
The ActRIIB-Fc protein used in the present study is
similar, but not identical to the one originally generated
by Se-Jin Lee [25]. The in house production of this re-
combinant protein has been described earlier [26].
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Shortly, the protein contains the ectodomain of human
ActRIIB linked to IgG1-Fc and was expressed in Chinese
hamster ovary (CHO) cells grown in a suspension culture.
Voluntary wheel running
As studies have shown that voluntary wheel running may
benefit mdx mice in terms of muscle properties [27] and
can also have positive effects on murine bones [15], it was
chosen as the exercise modality for this study. The mice
had free access to custom-made running wheels and the
total running distance was recorded 24 h daily.
Muscle mass and body weight measurement
The mice were weighed once every seven days to meas-
ure their body weight. After euthanization of the ani-
mals, gastrocnemius and quadriceps femoris muscles
were collected and weighed immediately after dissection.
Micro-computed tomography (μCT) analysis
X-Ray Micro-computed tomography of the distal femur
and second lumbar vertebrae were done with SkyScan
1070 μCT scanner (SkyScan, Kontich, Belgium) to assess
the microarchitecture of trabecular bone. Femur and
lumbar vertebrae samples were placed in to plastic tubes
and sealed with paraffin to minimize sample mobility.
Scanning parameters included a voxel resolution of 5.33
μm, X-ray potential of 70kVp, current of 200uA and an in-
tegration time of 3900ms. The object rotated in 0.45° steps
throughout the scanning for a total revolution of 182.45°.
Reconstruction of the scanned images was done
(Nrecon 1.4, Skyscan) with identical settings (misalign-
ment < 3, ring artifacts reduction 11, beam hardening cor-
rection 95%, and intensity gap 0.017–0.13). The regions of
interest were drawn blindly (CTan 1.4.4, SkyScan). The
corresponding starting points for the trabecular analysis
were 120 layers (2.4mm) proximally of the distal femoral
growth plate and 150 layers (3mm) distally of the cranial
growth plate of the 2nd lumbar vertebrae. The regions of
interest (ROIs) were extended 150 layers (3mm) with a
new ROI drawn every 10 layers (0.2mm). For the cortical
analysis the ROI was drawn around the cortical bone of
the femoral diaphysis, 600 layers (12mm) proximally of
the distal growth plate, ranging 100 layers (2mm) in the
proximal-distal plane. Finally the 3D, 2D and bone min-
eral density results were converted into numerical data for
statistical analyses.
Histological analysis
Femur samples were formalin-fixed, decalcified in EDTA,
embedded in paraffin and sectioned using a microtome.
The sectioned slides were deparaffinized, rehydrated and
stained by either Hematoxylin & eosin or a tartrate resist-
ant acid phosphatase (TRACP) stain and then counter-
stained with Mayer’s hematoxylin according to the
manufacturer’s instructions. The trabecular bone architec-
ture and osteoclasts were then analyzed blindly using
Osteomeasure-histomorphometry work station (Osteo-
metrics, USA). The analyzed area was defined as 800μm x
1200μm starting from 400μm proximally to the distal
growth plate excluding the cortical bone borders. The
region of interest was analyzed from three slices and
the mean of each parameter was used as the corre-
sponding value.
Quantitative real-time PCR
To analyze the molecular effects of ActRIIB-Fc on bone
C57Bl/6 F mice were administered with either PBS or
ActRIIB-Fc (5mg/kg) once a week for 8 weeks (n = 6-7
per group). RNA was extracted from the right femur by
performing an osteotomy to the distal and proximal
ends of the bone and briefly centrifuging it to remove
the bone marrow. The RNA was isolated using RNeasy
minikit (Qiagen, Germany). The cDNA was synthesized
from 1μg of RNA with SensiFAST probekit (Bioline,
UK) before performing quantitative real-time PCR using
iQ SYBR Green Supermix (Bio-Rad laboratories, USA).
The relative mRNA expression levels were then quanti-
fied using the 2-ΔΔCT method. β-actin was used as the
internal control.
Testing of mechanical properties
The mechanical properties of the femur and tibia
were determined by a three-point bending test using
biomechanical testing device (Mecmesin, West Sussex,
UK). The femur was positioned horizontally with the
anterior surface upward, centered on the supports
(span = 9mm); and the middle point of the femoral
and tibial shaft were vertically compressed at a con-
stant speed of 4.5mm/min, and data was collected at
a sampling rate of 10Hz until failure. The measured
data was converted to a load-displacement curve in a
Primer Forward sequence Reverse sequence
β-actin CGTGGGCCGCCCTAGGCACCA TTGGCCTTAGGGTTCAGGGGG
Runx2 GCCCAGGCGTATTTCAGA TGCCTGGCTCTTCTTACTGAG
Col1a1 GAGCGGAGAGTACTGGATCG GCTTCTTTTCCTTGGGGTTC
Opn ATCTGGGTGCAGGCTGTAA CCCGGTGAAAGTGACTGATT
Dmp-1 TTGGGATGCGATTCCTCTAC GGTTTTGACCTTGTGGGAAA
Sost GCAGCTGTACTCGGACACATC TCCTGAGAACAACCAGACCA
Dkk-1 GACAACTACCAGCCCTACCC GATCTGTACACCTCCGACGC
Rankl TGAAGACACACTACCTGACTCCTG CCACAATGTGTTGCAGTTCC
Opg ACCCAGAAACTGGTCATCAGC CTGCAATACACACACTCATCACT
TrAcp5 CGTCTCTGCACAGATTGCAT AAGCGCAAACGGTAGTAAGG
Ctsk AGGCATTGACTCTGAAGATGCT TCCCCACAGGAATCTCTCTG
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monitoring recorder linked to the tester. The max-
imum force and deformation and the break force and
deformation were read respectively from the highest
point of the load-deformation curve and from the
failure point. Stiffness was calculated as the slope of
the curve, which was fitted in the linear part of the
load-deformation curve.
Statistical analyses
Two-way analysis of variance (2x2 ANOVA) was used
for statistical evaluation and Student’s T-test as a post
hoc test with the statistical significance set to p < 0.05.
Results
Treatment with soluble ActRIIB-Fc increases body weight
and muscle mass
This is a follow-up study of Hulmi et al. 2013 and the
muscle and body weight results have been published pre-
viously [28, 29]. In brief, our results show that the muscle
mass increased in the ActRIIB-Fc treated groups. A sig-
nificant change in the masses of both the gastrocnemius
muscles and quadriceps femoris muscles was noted when
comparing ActRIIB-Fc and PBS groups to each other. The
running ActRIIB-Fc-R mice also developed larger muscle
mass compared to the running PBS-R group but changes
were more modest compared to the non-running groups.
As expected both active and sedentary ActRIIB-Fc
treated mice also had a significant increase in body
weight compared to their respective PBS controls. How-
ever, both running groups gained less weight during the
experiment and weighed less also at the end compared
to non-runners, mainly due to decreased fat mass as
published earlier [15]. Therefore at the end of the experi-
ment the bodyweight was equal in the ActRIIB-Fc-R and
PBS groups. The final mean weights for the mice per
group were as follows: PBS 30.3 ± 0.8g, ActRIIB-Fc 34.0 ±
1.9g, PBS-R 29.7 ± 1.7g and ActRIIB-Fc-R 31.6 ± 2.3g.
ActRIIB-Fc increases bone volume and bone mineral
density in appendicular skeleton
The μCT analysis of the distal femur showed a remark-
able increase in bone mass in the ActRIIB-Fc-treated
mice (ActRIIB-Fc effect ANOVA: p < 0.001) and this ef-
fect of ActRIIB-Fc was seen in both running and seden-
tary mice (Fig. 1). Bone volume and trabecular number
(Fig. 1c-d) were increased in ActRIIB-Fc treated seden-
tary mice by over 80% and over 70% (p < 0.001), respect-
ively. Volumetric bone mineral density (vBMD) (Fig. 1f )
increased in the ActRIIB-Fc treatment group and the
separation (Fig. 1e) between trabeculae also decreased
(ActRIIB-Fc effect p < 0.001). These results demonstrate
larger, more numerous trabeculae that are located more
closely to each other resulting in a more dense tissue
compared to PBS controls, when activin receptor ligand
signaling is inhibited. Running alone had little effect on
bone volume and trabecular number in PBS-treated
mice. In addition, there was no significant difference in
trabecular bone structure or vBMD between the
ActRIIB-Fc and ActRIIB-Fc-R groups indicating that
running did not further improve bone architecture in
ActRIIB-Fc-treated mice (ANOVA ActRIIB-Fc x running
interaction effect p = 0.434). The cortical bone analysis
of the femoral mid-shaft that ActRIIB-Fc treatment, with
and without running, increased cortical thickness by
14% (p < 0.05 in both) when comparing to PBS controls
(Fig. 1g). Running alone also resulted in a 10% increase
(p < 0.05 compared to sedentary PBS group) in cortical
thickness. Mean total cross-sectional bone area was also
increased by 10% by ActRIIB-Fc treatment and running
(Fig. 1h). However, there was no additional effect on ei-
ther cortical thickness or area by the combination of
ActRIIB-Fc and running (ANOVA ActRIIB-Fc x running
interaction effect p = 0.436 and p = 0.421, respectively).
ActRIIB-Fc treatment results in increased bone mass also
in axial skeleton
We also wanted to assess whether the treatment with
ActRIIB-Fc only affected weight bearing long bones or if
the axial skeleton was involved as well. For this purpose we
performed μCTanalysis on the second lumbar vertebrae.
The ActRIIB-Fc treatment-induced changes in the
vertebrae were similar but more modest compared to
the distal femur (Fig. 2). Bone volume (Fig. 2c) was
increased by 20% and trabecular number (Fig. 2d) by
30% in the ActRIIB-Fc-treated mice compared to PBS
group (p < 0.001). Similar to the femur analysis, bone
mineral density (Fig. 2e) was also increased and trabecular
separation (Fig. 2f) decreased (ActRIIB-Fc effect p < 0.05).
Running seemed to induce an increase in trabecular bone
volume and vBMD in vertebrae when comparing PBS-R
to the PBS-controls (running effect p < 0.05). As noted
previously for femur, the combined effect of ActRIIB-Fc
and running on vertebral bone did not significantly differ
from the effect of ActRIIB-Fc treatment alone.
ActRIIB-Fc decreases the number of osteoclasts on
trabecular bone
Histological analysis of distal femur confirmed our find-
ings in μCT analyses of increased bone volume per
tissue volume and trabecular number in the ActRIIB-
Fc-treated mice (Fig. 3). Interestingly, a decrease in
osteoclast number (N.Oc/B.Pm) was also observed
(Fig. 3h). This suggests that in addition to its published
effects on bone formation ActRIIB-Fc treatment sup-
presses osteoclast differentiation and therefore inhibits
bone resorption.
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ActRIIB-Fc treatment increases expression of osteoblast
markers and decreases expression of osteoclast markers
To further investigate the mechanisms behind these
effects we treated C57Bl mice with ActRIIB-Fc or ve-
hicle, collected bone samples and measured the ex-
pression of essential osteoblast and osteoclast marker
genes. qPCR analysis (Fig. 4) revealed increased ex-
pression of characteristic osteoblast markers (Col1A1
+ 80% p = 0.05, OPN +55% p < 0.05) and osteocyte
marker (DMP-1 + 125% p < 0.01) as well as decreased
expression of RANKL (-44% p < 0.01) a regulator of
bone resorption. There was also a trend of decreased
TRAP expression (-33% p = 0.1) in the treated group.
These results suggest that ActRIIB-Fc simultaneously
increases osteoblast induced bone formation and de-
creases bone resorption.
Treatment with ActRIIB-Fc improves mechanical strength
To test whether treatment with ActRIIB-Fc would also
improve the mechanical properties of long bones, we
performed a three point bending test on femurs and tib-
ias. There was a significant increase in stiffness and bone
strength in the ActRIIB-Fc-treated compared to the PBS
group in sedentary mice (Fig. 5). Running alone resulted
in a trend of stiffer and stronger bones but this did not
appear to be statistically significant. In addition, volun-
tary running did not further improve bone biomechan-
ical properties in the running ActRIIB-Fc-treated mice.
Fig. 1 Reconstructed 3D images of the distal femur of control (a) and Act-R-Fc treated mice (b) showing a significant increase in bone mass in
the treated group. μCT analysis of the distal femur showing (c) increased bone volume (BV/TV), (d) trabecular numbers (Tb.N), (e) decreased
trabecular separation and (f) increased volumetric bone mineral density (vBMD) in ActRIIB-Fc-treated mice compared to controls. Significant
increases in (g) cortical thickness and (h) mean total cross-area parameters were also noted. Running combined with ActRIIB-Fc treatment did
not further improve these parameters N = 7-9 per group. # = p < 0.05 compared to PBS, * = p < 0.05 compared to PBS-R
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To further explore the effects of ActRIIB-Fc treatment
on bone tissue, the results were then adjusted with body
mass acting as the covariate. After adjustment minor
changes could only be seen in the μCT analysis of the
vertebrae that did not affect the interpretation of the
results. Therefore the differences between the body
weights of the mice did not seem to significantly affect
the results of our analyses. The datasets analyzed during
the current study are available from the corresponding
author upon request.
Discussion
In this study we evaluated the effects of inhibition of
ActRIIB ligands on bone and muscle tissue using a soluble
activin type IIB-receptor in an mdx mouse model. We also
aimed to test whether voluntary physical activity com-
bined with ActRIIB-Fc treatment would have an effect on
these tissues. Our results indeed confirm our hypotheses.
First, we were able to show a significant increase in bone
mass in ActRIIB-Fc treated mice compared to PBS treated
control mice. Second, our findings demonstrate that
ActRIIB-Fc affects both appendicular and axial bone mass
and beneficially modifies biomechanical properties of long
bones. Finally, although exercise alone had some positive
effects on bone structure, combination of running exercise
with ActRIIB-Fc did not further increase bone mass or
strength compared to ActRIIB-Fc treatment alone.
Our μCT results of the distal femur showed that the
ActRIIB-Fc treatment resulted in increased vBMD, num-
ber of bone trabeculae and increased bone volume. The
separation of trabeculae was also decreased. Our find-
ings are consistent with previous reports demonstrating
that treatment with either ActRIIA-Fc [6, 8] or ActRIIB-
Fc [9, 10] resulted in increased bone volume. Increased
BMD in trabecular bone also suggests that at least part
of the effect could be derived from decreased bone re-
sorption, possibly due to slower bone turnover and pro-
longed secondary mineralization and filling of resorption
Fig. 2 Reconstructed 3D images of the 2nd lumbar vertebrae also showing a noticeable difference in bone mass between the control (a) and
treatment group (b). Similar to the distal femur, (c) bone volume (BV/TV), (d) trabecular number (Tb.N) and (e) volumetric bone mineral density
(vBMD) were increased while (f) trabecular separation (Tb. Sp) was decreased in ActRIIB-Fc-treated mice compared to controls. ActRIIB-Fc and
running did not result in further beneficial effect. # = p < 0.05 compared to PBS, * = p < 0.05 compared to PBS-R
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spaces. However, it was interesting to note that the dif-
ferences between ActRIIB-Fc and ActRIIB-Fc-R groups
were miniscule showing that physical activity did not
have a noticeable further effect on trabecular bone in
the murine femur in this model. ActRIIB-Fc-R mice ran
significantly less especially in the beginning of the study
as previously reported [26], which could at least in part
explain the lack of additional effect of running on bone
mass or strength in the ActRIIB-Fc-R group. The non-
significant change between PBS and PBS running group
in bone mineral density was also surprising suggesting
that physical activity in a form of voluntary running does
not greatly affect bone quality in long bones in young
mdx mice.
In humans, weight bearing exercise has positive effects
on the bones of young individuals and voluntary running
may have positive effects on murine bones [30]. However,
as often rather high intensity/volume of exercise is
needed for positive effects on bone, our training modal-
ity might have been of too low intensity to induce more
robust effects on bone mass [14]. In contrast to our re-
sults, Hamrick et al. suggested that the combination of
exercise and increased muscle mass in myostatin-
deficient mice has a much greater effect on bone
strength than exercise or muscle mass alone [31]. This
could be explained by the fact that the myostatin-
deficient mice used in their study had increased lean
mass postnatally and this increased contractile forces
induced by locomotion and resulted in a more powerful
mechanotransduction effect on bones. In addition, their
exercise regime based on force exercise was most likely
more intense compared to our method of voluntary ex-
ercise. Finally, as Hamrick et al. analyzed the radius,
they stated that their effects could be partly explained
Fig. 3 Histological images (H&E staining) of the distal femur showing an increase of trabecular numbers in ActRIIB-Fc treated group (b) compared
to PBS controls (a). TRACP staining of distal femurs of control (c) and Act-R-Fc treated mice (d). Histomorphometric analysis showed increased
bone volume (e) and trabecular number (f) and decreased trabecular separation (g) as in μCT. Interestingly, the number of TRACP positive
osteoclasts was reduced in Act-R-Fc-treated mice (h). The region of interest from which the trabecular islands and the stained osteoclasts
were analyzed consisted of an 800μm x 1200μm area near the distal growth plate. N = 8-9 per group. # = p < 0.05 compared to PBS
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Fig. 4 qPCR analyses show changes in the expression of key markers for bone metabolism. Abbreviations in order: Runt related transcription
factor 2, Type I collagen, Osteopontin, Dentin matrix protein 1, Sclerostin, Dickkopf-related protein 1, Receptor activator of nuclear factor kappa-B
ligand, Osteoprotegerin, Tartrate resistant acid phosphatase, Cathepsin K. N = 6-7 per group. * = p≤ 0.05 compared to PBS group
Fig. 5 Biomechanical testing of femurs and tibias. A significant increase in both maximum force and stiffness was measured in the Act-R-Fc
treated mice compared to the control group. However there was no statistical significance between the ActRIIB-Fc-treated and control running
groups. N = 7-9 per group. # = p < 0.05 compared to PBS, * = p < 0.05 compared to PBS-R
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by the difference in the load induced by the curvature
of the bone they analyzed.
The effect of ActRIIB-Fc treatment was also seen in sec-
ond lumbar vertebrae but it was more modest than in dis-
tal femur analysis. Bone volume was increased by 22% in
vertebrae compared to 83% in the femur. Our results on
lumbar vertebrae are consistent with the article published
by Bialek et al., in which they used normal C57Bl mice [9].
As in femur, voluntary physical activity combined with
ActRIIB-Fc treatment did not have a synergistic effect in
vertebrae. Trabecular numbers increased only marginally
and the increases in bone volume and volumetric bone
mineral density were not statistically significant.
Improved cortical geometry in long bones also trans-
lated into significantly improved biomechanical proper-
ties as both the maximal failure load as well as stiffness
increased in the femurs and tibias of ActRIIB-Fc treated
mice. Bialek et al [9] also reported that ActRIIB-Fc treat-
ment increased bone strength when compared to vehicle
group but found this only in the L4 vertebrae. In our
study voluntary running did not have statistically signifi-
cant effect on bone strength although there was a posi-
tive trend in both failure load and stiffness. This lack of
effect could be due to the relatively small sample size.
Histological analysis of the distal femur comparing
PBS and ActRIIB-Fc groups was done to assess the effect
of blockage of ActRIIB-ligands on osteoclast parameters.
Histological analysis confirmed the increase in bone vol-
ume and trabecular number as was noticed in μCT.
However, we also found a significant decrease in the
number of osteoclasts per bone perimeter in the
ActRIIB-Fc treated animals. This suggests a suppression
of osteoclast differentiation and subsequently bone re-
sorption that has not previously been reported with
ActRIIB-Fc. As discussed above, this finding is in agree-
ment with the increased trabecular vBMD in the distal
femur observed with μCT. Activin A has been shown to
induce osteoclast differentiation in vitro and in vivo
[32–35], although some reports suggest a negative effect
on survival and motility of mature osteoclasts [36]. The
decreased osteoclast number in our study supports the
role for activin A to induce osteoclast differentiation, al-
though we cannot exclude the possible effect of other li-
gands binding to ActRIIB-Fc. In addition, ActRIIB ligand
inhibition could also affect the osteoblast-dependent
regulation of osteoclastogenesis. Previous studies have
shown that blocking of activin receptor ligands results in
increased bone formation translating into increased bone
mass. Unfortunately, the simultaneous signaling and
metabolic analyses of muscle tissues performed in this
study [26] and the limited number of animals available
prevented us from using fluorochromes to measure bone
formation in mice. However, based on the very robust
increase in trabecular bone volume, gene expression
discussed below and the previously published data, it is
very likely that ActRIIB-Fc molecule used in our study
also induced an increase in bone formation.
Our results also provide novel data regarding the mo-
lecular mechanism behind the effects of ActRIIB-Fc on
bone growth. We were able to show that ActRIIB-Fc in-
duces an increase in osteoblast and osteocyte gene
markers suggesting that ActRIIB-Fc indeed also has an
anabolic effect on bone. Furthermore we were able to con-
firm our hypothesis of ActRIIB-Fc acting as a suppressor
of osteoclast activity as the expression of osteoclast
markers decreased noticeably. Interestingly, expression of
DKK-1 and sclerostin, key markers for negative regulation
of WNT signaling, also significantly increased. This could
be due to negative feedback loop induced by increased
bone mass and/or reflect enhanced Wnt signaling. Alter-
natively, the concomitantly increased osteocyte number
could also contribute to the increased expression of DKK1
and sclerostin.
Based on the present experiment, the molecular basis
for the effects of ActRIIB-Fc treatment and running on
bone tissue, independent of increased body and muscle
mass, remain unclear. If ActRIIB-Fc and running have
independent signaling pathways for bone adaption, one
would have expected an additive effect. However, investi-
gating this interaction is encumbered by the marked ef-
fect of running on body mass, and the inextricable link
between the body and skeletal size. On the other hand,
adjusting the data to body weight did not significantly
alter the results on bone structure or strength. Consider-
ing the effectiveness of the interventions in isolation, the
results indicated a clear and robust skeletal effect by
ActRIIB-Fc. However, judging by the PBS groups the ef-
fects of the running intervention on skeletal mass were
much more modest, and could not be observed in the
femur analysis. Clearly, from the two interventions ap-
plied in the present study, ActRIIB-Fc was more effective,
as we expected. Therefore our study provides promising
evidence that ActRIIB-Fc could be applied as a therapeutic
agent in musculoskeletal disorders where physical activity
is limited.
It is also notable that as soluble activin receptors also
bind other growth factors in addition to activin A
[23, 37]. It remains unclear which is/are the main ef-
fectors inducing the observed alterations. Activin A sup-
presses bone formation and induces resorption and is
therefore the primary suspect for direct bone effects of
ActRIIB-Fc, but inhibition of other growth factors may
also contribute. Most likely the majority of the effect on
bone is derived from direct regulation of bone cell func-
tions. However, due to the known muscle-bone interac-
tions it is also possible that some of the positive effects on
bone could stem from simultaneous increase in muscle
mass either via increased body mass or by direct
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molecular cross talk between muscle and bone tissues.
As adjusting for the body mass did not alter the results
the effect would likely be direct signaling between the
tissues. Further molecular studies are needed to clarify
this question.
Conclusions
In conclusion, we show here that inhibition of activin
receptor ligand signaling using ActRIIB-Fc positively af-
fects bone mass and quality and subsequently bone mech-
anical strength, without further positive effect by physical
exercise. Soluble ActRIIB-Fc could provide an intriguing
approach for the treatment of coexisting muscle and bone
loss in many diseases, aging and in injuries.
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